117 related articles for article (PubMed ID: 20975258)
21. Thyrotoxicosis during sunitinib treatment for renal cell carcinoma.
Grossmann M; Premaratne E; Desai J; Davis ID
Clin Endocrinol (Oxf); 2008 Oct; 69(4):669-72. PubMed ID: 18394019
[TBL] [Abstract][Full Text] [Related]
22. Secondary erythrocytosis produced by the tyrosine kinase inhibitors sunitinib and sorafenib.
Alexandrescu DT; McClure R; Farzanmehr H; Dasanu CA
J Clin Oncol; 2008 Aug; 26(24):4047-8. PubMed ID: 18711201
[No Abstract] [Full Text] [Related]
23. [Adverse effects of the tyrosine-kinase inhibitor sunitinib, a new drug for the treatment of advanced renal-cell cancer].
van der Veldt AA; van den Eertwegh AJ; Boven E
Ned Tijdschr Geneeskd; 2007 May; 151(20):1142-7. PubMed ID: 17557672
[TBL] [Abstract][Full Text] [Related]
24. Sunitinib-related fulminant hepatic failure: case report and review of the literature.
Mueller EW; Rockey ML; Rashkin MC
Pharmacotherapy; 2008 Aug; 28(8):1066-70. PubMed ID: 18657022
[TBL] [Abstract][Full Text] [Related]
25. Sunitinib may raise the risk of bisphosphonate-related osteonecrosis of the jaw: presentation of three cases.
Hoefert S; Eufinger H
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2010 Oct; 110(4):463-9. PubMed ID: 20692189
[TBL] [Abstract][Full Text] [Related]
26. Shrinkage of thyroid volume in sunitinib-treated patients with renal-cell carcinoma: a potential marker of irreversible thyroid dysfunction?
Rogiers A; Wolter P; Op de Beeck K; Thijs M; Decallonne B; Schöffski P
Thyroid; 2010 Mar; 20(3):317-22. PubMed ID: 20144039
[TBL] [Abstract][Full Text] [Related]
27. Acalculous cholecystitis in a patient with metastatic renal cell carcinoma treated with sunitinib.
Gomez-Abuin G; Karam AA; Mezzadri NA; Bas CA
Clin Genitourin Cancer; 2009 Jan; 7(1):62-3. PubMed ID: 19213671
[TBL] [Abstract][Full Text] [Related]
28. A case of acute haemolysis with 2 different multi target thyrosine kinase inhibitors in a patient with renal cancer.
Berchem G; Dewilde S; Mahassen P
Bull Soc Sci Med Grand Duche Luxemb; 2009; (1):7-9. PubMed ID: 19514172
[TBL] [Abstract][Full Text] [Related]
29. [Treatment with sunitinib and hypothyroidism--a case report and overview of literature].
Kreze A; Stáhalová V; Zadrazilová A; Koskuba J; Kosák M
Klin Onkol; 2009; 22(4):176-8. PubMed ID: 19731880
[TBL] [Abstract][Full Text] [Related]
30. [Medical treatment of metastatic renal cell carcinoma after the approval and market entry of multitargeted tyrosine kinase inhibitors in Germany].
Bolenz C; Trojan L; Honeck P; Schöppler G; Herrmann E; Alken P; Michel MS; Häcker A
Aktuelle Urol; 2009 Jan; 40(1):31-6. PubMed ID: 19177319
[TBL] [Abstract][Full Text] [Related]
31. Sunitinib, hypertension, and heart failure: a model for kinase inhibitor-mediated cardiotoxicity.
Gupta R; Maitland ML
Curr Hypertens Rep; 2011 Dec; 13(6):430-5. PubMed ID: 21931979
[TBL] [Abstract][Full Text] [Related]
32. Food and Drug Administration drug approval summary: Sunitinib malate for the treatment of gastrointestinal stromal tumor and advanced renal cell carcinoma.
Rock EP; Goodman V; Jiang JX; Mahjoob K; Verbois SL; Morse D; Dagher R; Justice R; Pazdur R
Oncologist; 2007 Jan; 12(1):107-13. PubMed ID: 17227905
[TBL] [Abstract][Full Text] [Related]
33. Sunitinib-induced acute hemolysis without hypertension: a case report.
Jain R; Mathew P; Wood CG; Tannir NM
Clin Genitourin Cancer; 2008 Sep; 6(2):122-3. PubMed ID: 18824436
[TBL] [Abstract][Full Text] [Related]
34. [Thyroid dysfunction in patients with advanced renal cell carcinoma treated with sunitinib: a multifactorial issue].
Fuertes Zamorano N; De Miguel Novoa MP; Molino González A; Díaz Pérez JÁ; Rojas-Marcos PM; Montañez Zorrilla MC
Endocrinol Nutr; 2010 Dec; 57(10):486-91. PubMed ID: 20702151
[TBL] [Abstract][Full Text] [Related]
35. Frequent dose interruptions are required for patients receiving oral kinase inhibitor therapy for advanced renal cell carcinoma.
La Vine DB; Coleman TA; Davis CH; Carbonell CE; Davis WB
Am J Clin Oncol; 2010 Jun; 33(3):217-20. PubMed ID: 19745694
[TBL] [Abstract][Full Text] [Related]
36. Severe cardiomyopathy in a patient with renal cell carcinoma after treatment with the novel tyrosine kinase inhibitor sunitinib.
Chorianopoulos E; Jäger D; Katus HA; Frey N
Clin Res Cardiol; 2007 Nov; 96(11):829-30. PubMed ID: 17694380
[No Abstract] [Full Text] [Related]
37. Sunitinib for the management of advanced renal cell carcinoma.
Escudier B
Expert Rev Anticancer Ther; 2010 Mar; 10(3):305-17. PubMed ID: 20214511
[TBL] [Abstract][Full Text] [Related]
38. Sunitinib-induced microangiopathic hemolytic anemia with fatal outcome.
Talebi TN; Stefanovic A; Merchan J; Lian E; Silva O
Am J Ther; 2012 Jul; 19(4):e143-5. PubMed ID: 21403468
[TBL] [Abstract][Full Text] [Related]
39. Acute nephritic syndrome after anti-VEGF therapy for renal cell carcinoma.
Rolleman EJ; Weening J; Betjes MG
Nephrol Dial Transplant; 2009 Jun; 24(6):2002-3. PubMed ID: 19332867
[No Abstract] [Full Text] [Related]
40. Skin depigmentation induced by sunitinib treatment of renal cell carcinoma.
Al Enazi MM; Kadry R; Mitwali H
J Am Acad Dermatol; 2009 Nov; 61(5):905-6. PubMed ID: 19836653
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]